San Francisco, 15 May 2025: The Report Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 – 2030

The global peptide antibiotics market size is estimated to reach USD 6.64 billion by 2030, expanding at a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin’s lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin’s lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin’s lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

The rising demand in hospitals and clinics primarily drives market growth. Key factors include the increasing prevalence of bacterial skin infections, bloodstream infections, and hospital-acquired infections. In addition, the market is bolstered by a surge in product approvals and new product launches, which are expected to further accelerate growth during the forecast period.

Request sample report of Peptide Antibiotics Market@ https://www.grandviewresearch.com/industry-analysis/peptide-antibiotics-market-report/request/rs1

The significant prevalence of MRSA underscores the growing challenge of antibiotic resistance globally. A 2023  study published in the Journal of Antimicrobial Resistance & Infection Control reported a global prevalence of MRSA (Methicillin-resistant Staphylococcus aureus) at approximately 14.69%. The growing burden of MRSA infections is expected to drive demand for drugs, which offer targeted mechanisms of action and reduced likelihood of resistance compared to traditional antibiotics. As a result, the market will likely witness robust growth over the forecast period, propelled by their potential to effectively address resistant bacterial strains.

Technological advancements in drug development are significantly transforming the landscape of antimicrobial therapies. Innovations in bioengineering and synthetic biology have enabled the design of highly targeted peptide-based drugs with enhanced stability, potency, and reduced toxicity. Techniques such as peptide modification, conjugation with nanoparticles, and computational modeling are optimizing their pharmacokinetics and effectiveness against resistant pathogens like MRSA.

Moreover, advances in large-scale manufacturing processes, including recombinant DNA technology and solid-phase peptide synthesis (SPPS), reduce production costs and improve scalability. For instance, in July 2024 , Vapourtec introduced the Peptide-ExplorerLT, a new system designed to support chemists in optimizing and exploring linear peptide synthesis. Building on the success of the original Peptide-Explorer launched in 2020, the Peptide-ExplorerLT delivers the same high-quality peptide production capabilities while offering a more compact design and a more affordable price point, making it accessible to a broader range of users. These breakthroughs are paving the way for next-generation peptide antibiotics that address the limitations of conventional treatments and align with the growing demand for innovative solutions in combating antibiotic resistance.